Pharmaceutical

Imvotamab by IGM Biosciences for Rheumatoid Arthritis: Likelihood of Approval

Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Rheumatoid Arthritis.

Dec 22, 2023 - 18:00
Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Rheumatoid Arthritis.
Read the original article

Tags:

Previous Article

XB-002 by Exelixis for Breast Cancer: Likelihood of Approval

Next Article

MRNA-2752 by Moderna for Transitional Cell Cancer (Urothelial Cell Cancer): Like...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Johnson & Johnson antiviral pill for dengue shows early efficacy

Johnson & Johnson antiviral pill for dengue shows early...

Oct 24, 2023

STAT+: Drug from Stoke shows lower activity against childhood epilepsy, prompting search for better dose

STAT+: Drug from Stoke shows lower activity against chi...

Jul 26, 2023

Can reforms restore faith in India’s pharma industry after cough syrup scandals?

Can reforms restore faith in India’s pharma industry af...

Sep 29, 2023